US FDA Forced To Rip Up, Start Biosimilar First Interchangeable Exclusivity Guidance Again

 
• By Derrick Gingery
  
New fact patterns forced the FDA to restart first interchangeable biosimilar exclusivity guidance development. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Legal & IP